More lease deals reached for Hudson's Bay locations
TORONTO — Hudson's Bay has reached deals to sell the leases of six store locations as legal wrangling continues on work to close a deal to sell up to 25 leases to B.C. billionaire Ruby Liu.
Legal filings show clothing retailer YM Inc. has struck a deal to buy five leases for $5.03 million, while it was unable to secure landlord approvals for three other locations.
The five leases include Vaughan Mills in Vaughan, Ont., Tanger Outlet in Kanata, Ont., Outlet Collection in Winnipeg, CrossIron Mills in Rocky View, Alta., and Toronto Premium Outlets in Halton Hills, Ont.
Separately, Ivanhoe Realties Inc. has agreed to pay $20,000 for a lease at Metrotown in Burnaby, B.C., that its parent company Ivanhoe Cambridge owns.
Hudson's Bay put its leases up for sale earlier this year, after it filed for creditor protection and closed its 80 stores and 16 under its sister Saks banners.
Three leases which sold for $6 million were already transferred to Liu who wants to buy 25 more to open a department store.
---
This report by The Canadian Press was first published July 25, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
Why Bloom Energy Stock Is Powering Higher This Week
Key Points Bloom Energy reported a new deal with Oracle last week. An analyst upwardly revised the price target on Bloom Energy stock. The company continues to report growing revenue and earnings before interest, taxes, depreciaiton, and amortization. 10 stocks we like better than Bloom Energy › Soaring 43.6% from the start of July through the end of trading last week, the stock of Bloom Energy (NYSE: BE) has been red hot this month. And the trend seems to be continuing through the remainder of the month. Although the company didn't have any news to report that explains the fuel cell maker's rise this week, it's clear that the market's appetite for Bloom Energy remains strong. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » According to data provided by S&P Global Market Intelligence, shares have risen 9.2% from the end of last Friday's session through 2:05 p.m. ET today. Bloom is blossoming in investors' eyes thanks to this opportunity Investors leaped at the opportunity to power their portfolios with the stock last week after the company announced a deal with Oracle for the deployment of fuel cells to power data centers, and the enthusiasm is continuing into this week as well. Nuclear energy stocks have emerged as one of the most appealing alternative energy options for companies operating data centers, but the deal with Oracle suggests that Bloom Energy might have a robust new opportunity considering the massive amounts of capital that artificial intelligence (AI) companies are investing in data centers. Another source of the market's ebullience is an analyst's auspicious outlook. Last Friday, UBS analyst Manav Gupta boosted the price target on Bloom to $51 from $29 due to the company's deal with Oracle. Is Bloom ready to wilt, or is there still room to run? While the Oracle deal and the analyst's revised price target are understandable reasons for shares to rise, it's important to acknowledge that there are more tangible reasons for buying the stock. BE Revenue (Annual) data by YCharts. Bloom Energy is growing both revenue and earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a hopeful sign that the company will succeed in a way that its peers have not. This makes Bloom Energy worth further investigation for fuel cell exposure. Should you invest $1,000 in Bloom Energy right now? Before you buy stock in Bloom Energy, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bloom Energy wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
National Post
19 minutes ago
- National Post
As Toronto aims to ban motorized craft at popular beach, some blame 'bad actors'
Article content But some watercraft rental companies say despite following all the rules, they are being lumped in with a few 'bad actors' that are ruining operations for the rest through unsafe business practices. They are urging city council to reconsider the latest ban along Toronto's shores. Article content Raj Mehta, one of the founders of rental company Jetti, said that while he supports cracking down on unsafe and irresponsible operators, watercraft bans at city beaches also penalize businesses like his that operate safely. Article content 'We're at the ramp and on the water almost every day and we witness the safety issues the city is bringing up,' he said. 'There are some operators that should not be operating.' Article content Jetti sends its watercraft out of Humber Bay West, an area outside of PortsToronto's jurisdiction, he said. Article content Mehta said his company follows safety regulations by having insurance, GPS-based speed controls on Jet Skis to respect no wake zones, and issues proof of competency through rental boat safety checklists. Article content 'We use the public dock but we don't actually leave any watercraft in the water … when they come back, we pull them onto trailers and they're out of here,' he said, adding that manyother operators leave their watercraft along the shore. Article content 'Anyone can go buy a few Jet Skis and call themselves a rental company and start renting these out because there is no regulation,' he said. 'These are the guys causing the safety issues, these are the people that are not respecting public space.' Article content Mehta said he is willing to work with the city to figure out a solution that would focus on regulation, such as setting up designated launches for personal watercraft away from public beaches and boat launch areas, or leasing space from the city. Article content Despite reaching out to a local councillor and the mayor's office, Mehta said he has not received responses to his proposals and requests. Article content Companies looking to work with the city can reach out and make proposals but 'none of that's happened,' Bradford said, adding that an amendment to his motion to create a stakeholder advisory committee could include rental companies. Article content While Bradford recognizes the entire industry isn't breaking operational and safety rules, based on his observations at Woodbine Beach he believes rental companies aren't interested in working with the city. He said they could look into leasing boat slips across the waterfront if they want to continue their operations. Article content Mehta said his company has already explored renting space from marinas but there are a 'whole bunch of issues' with that option as marinas in the inner harbour fall under PortsToronto's jurisdiction, which requires boaters to have specific permits that would be difficult to obtain for short-term renters. Article content 'Jet Ski usage tends to negatively impact boaters and the boating experience in the harbour, so marinas are unlikely to want to cater to Jet Ski companies,' said Riehl from PortsToronto, adding that no marina in its jurisdiction rents space to such operators. Article content Mehta said he still hopes the city can figure out a solution that prioritizes safe and fair access to the waterfront and doesn't push away those who are trying to follow the rules.
National Post
19 minutes ago
- National Post
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development
Article content LAVAL, Québec — Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation ('VoxCell'), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials. Article content This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell's high-resolution 3D bioprinted tissue platforms into Altasciences' discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies. Article content 'We're proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,' Article content said Steve Mason, Co-Chief Operating Officer at Altasciences. Article content 'This collaboration aligns with our commitment to the 3Rs as well as to innovative, efficient solutions that improve data quality and accelerate decisions for our clients.' Article content VoxCell's proprietary bioprinted tissues are engineered to closely mimic the complexity of human tumors and other biological structures, offering drug developers an advanced platform for evaluating efficacy, safety, and toxicity—before moving into animal or human studies. Article content 'Our mission has always been to make drug screening more human-relevant and predictive,' Article content said Karolina Valente, CEO of VoxCell BioInnovation. Article content 'Altasciences shares this forward-thinking approach, and we're excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.' Article content The collaboration will focus initially on drug screening for ocular indications, with plans to expand into additional therapeutic areas and applications. Article content This partnership represents a shared vision: to transform early-stage research through innovation, integration, and smarter science—delivering better outcomes for patients worldwide. Article content About Altasciences Article content Altasciences Article content preclinical Article content and Article content clinical pharmacology Article content studies, including Article content formulation, manufacturing, and analytical services Article content . For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include Article content , Article content clinical pharmacology and proof of concept Article content , Article content bioanalysis Article content , program management, Article content research support Article content , medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Article content . Article content About VoxCell BioInnovation Article content VoxCell BioInnovation Article content is a biotechnology startup founded in 2020 in Victoria, British Columbia, Canada. The company is dedicated to advancing the future of in vitro modeling by creating novel testing platforms for oncology research and drug development. Article content VoxCell develop 3D bioprinted vascularized human-like tissue models that closely replicate native biology, offering a powerful tool for predictive, physiologically relevant research. Using a proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™, they produce complex tissue models that mirror patient biopsy samples in structure and function. Article content Article content Article content Article content Contacts Article content Article content
